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Abstract
Background: Observational studies have shown that vitamin D binding protein (DBP) levels, a key determinant of 25-
hydroxy-vitamin D (25OHD) levels, and 25OHD levels themselves both associate with risk of disease. If 25OHD levels have a
causal influence on disease, and DBP lies in this causal pathway, then DBP levels should likewise be causally associated with
disease. We undertook a Mendelian randomization study to determine whether DBP levels have causal effects on common
calcemic and cardiometabolic disease.
Methods and Findings: We measured DBP and 25OHD levels in 2,254 individuals, followed for up to 10 y, in the Canadian
Multicentre Osteoporosis Study (CaMos). Using the single nucleotide polymorphism rs2282679 as an instrumental variable,
we applied Mendelian randomization methods to determine the causal effect of DBP on calcemic (osteoporosis and
hyperparathyroidism) and cardiometabolic diseases (hypertension, type 2 diabetes, coronary artery disease, and stroke) and
related traits, first in CaMos and then in large-scale genome-wide association study consortia. The effect allele was
associated with an age- and sex-adjusted decrease in DBP level of 27.4 mg/l (95% CI 24.7, 30.0; n = 2,254). DBP had a strong
observational and causal association with 25OHD levels (p = 3.2610219). While DBP levels were observationally associated
with calcium and body mass index (BMI), these associations were not supported by causal analyses. Despite well-powered
sample sizes from consortia, there were no associations of rs2282679 with any other traits and diseases: fasting glucose
(0.00 mmol/l [95% CI 20.01, 0.01]; p = 1.00; n = 46,186); fasting insulin (0.01 pmol/l [95% CI 20.00, 0.01,]; p = 0.22;
n = 46,186); BMI (0.00 kg/m2 [95% CI 20.01, 0.01]; p = 0.80; n = 127,587); bone mineral density (0.01 g/cm2 [95% CI 20.01,
0.03]; p = 0.36; n = 32,961); mean arterial pressure (20.06 mm Hg [95% CI 20.19, 0.07]); p = 0.36; n = 28,775); ischemic stroke
(odds ratio [OR] = 1.00 [95% CI 0.97, 1.04]; p = 0.92; n = 12,389/62,004 cases/controls); coronary artery disease (OR = 1.02 [95%
CI 0.99, 1.05]; p = 0.31; n = 22,233/64,762); or type 2 diabetes (OR = 1.01 [95% CI 0.97, 1.05]; p = 0.76; n = 9,580/53,810).
Conclusions: DBP has no demonstrable causal effect on any of the diseases or traits investigated here, except 25OHD levels.
It remains to be determined whether 25OHD has a causal effect on these outcomes independent of DBP.
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Introduction
Serum vitamin D levels are generally low in populations
worldwide [1,2]. Observational studies have implicated vitamin-
D-deficient states in several common diseases and related traits,
including cardiovascular disease [3–5], type 2 diabetes [6,7],
breast cancer [8], bladder cancer [9], colorectal cancer [10],
chronic lung diseases such as asthma, bronchiectasis, and other
lung infections [11–14]. Vitamin D may have modulatory effects
on the immune system and thus a potential effect on rheumato-
logic, inflammatory, and autoimmune diseases [15,16], such as
type 1 diabetes, inflammatory bowel disease [17], familial
Mediterranean fever [18], multiple sclerosis [19], and chronic
pain [20,21].
Although observational studies have shown associations be-
tween vitamin D deficiency (defined as serum 25-hydroxy-vitamin
D [25OHD] level ,50 nmol/l) and a number of common
diseases, it is not known whether these relationships are causal.
Similarly, while animal studies have provided some mechanistic
clues into possible causal pathways, mechanisms underlying the
associations between circulating 25OHD concentrations and
different diseases remain unclear. One key determinant of
25OHD levels is vitamin D binding protein (DBP), a group-
specific component of serum globulin [22]. DBP acts as the
principal protein carrier for serum 25OHD and activated vitamin
D, and thus functions as a reservoir for vitamin D metabolites [23].
Approximately 85%–90% of 25OHD is transported from the liver
to target organs bound to DBP [24]. DBP also affects the clearance
of vitamin D metabolites in part by aiding in the reabsorption of
filtered vitamin D metabolites through megalin in the kidney [25].
DBP is encoded by GC, which is located on Chromosome 4q13.
Genetic association testing of a single nucleotide polymorphism
(SNP) at GC, rs2282679, in the TwinsUK cohort (n = 1,674)
showed that this genetic variant was strongly associated with DBP
concentrations (p = 4.0610242) [26]. The Study of Underlying
Genetic Determinants of Vitamin D and Highly Related Traits
(SUNLIGHT), a large, multicenter genome-wide association study
(GWAS), demonstrated that rs2282679 was also strongly associ-
ated with reduced 25OHD concentrations (p = 1.96102109) [26].
Each copy of the effect allele, C, at rs2282579, lowered 25OHD
levels by an amount similar to that associated with daily vitamin D
supplementation [26]. Other genetic studies have also shown
robust associations between GC genetic variants and circulating
25OHD concentrations [26–29].
If vitamin D has a causal impact on common diseases and DBP
levels are a main determinant of 25OHD levels, DBP may lie in
the causal pathway between 25OHD and these conditions.
Indeed, DBP may have additional metabolic roles beyond vitamin
D transport. For example, it may modulate bone development,
innate immunity, and inflammatory responses [30–32]. DBP has
also been purportedly linked with autoimmune and inflammatory
diseases, aspirin resistance (i.e., failure of aspirin to inhibit platelet
function) [33], various arthritides [34], and cardiometabolic
outcomes [35–37]. Polymorphisms in the GC gene [38] have
been associated with oral glucose tolerance, fasting insulin levels
[39], fracture risk [40], and breast cancer [41]. Thus, observa-
tional evidence showing that differences in serum DBP levels are
associated with common diseases supports the hypothesis that
DBP may either be an intermediate in the biological pathway or
an upstream determinant influencing 25OHD effects on common
diseases. By way of analogy, it has been suggested that other
transporters of steroidal hormones, including sex hormone binding
globulin and corticosteroid binding globulin, are major effectors of
steroid action independent of their function as carriers [42].
We therefore examined whether DBP levels might be associated
with common diseases, potentially clarifying some of the
mechanisms underpinning the possible clinical effects of
25OHD. Mendelian randomization (MR) is a method used to
provide evidence for causal associations between a potentially
modifiable risk factor (e.g., DBP) and common diseases when a
randomized clinical trial is not possible [43]. The MR paradigm
relies on the random assortment of genetic variants at conception
to provide an un-confounded study design to estimate the causal
effects of an intermediate phenotype on an outcome measure of
interest (i.e., disease and related phenotypic traits) undistorted by
reverse causation [43]. Findings from such an analysis can
strengthen causal inferences from observational studies and could
therefore clarify whether DBP is in the causal pathway between
25OHD levels and disease.
Here, we first evaluated the causal impact of DBP levels on (1)
serum 25OHD concentrations, (2) 25OHD biological readouts,
such as parathyroid hormone (PTH) levels, and (3) common
cardiometabolic diseases that have been related to vitamin D
physiology and their associated traits, through a MR analysis
comprising two stages. In the first stage, we determined the effect
of DBP levels on these diseases and traits in a large, multicenter
cohort. In the second stage, we sought replication of findings in
large-scale international GWAS consortia, to achieve a maximal
sample size and precise effect estimates. We tested whether these




The Canadian Multicentre Osteoporosis Study (CaMos) pop-
ulation was used to describe the relationship between rs2282679,
25OHD, and DBP levels, and to produce instrumental variable
(IV) results on the causal effect of DBP levels on diseases and
related traits. CaMos is an ongoing population-based prospective
cohort study of 9,423 randomly selected community-dwelling
women (n = 6,539) and men (n = 2,884) aged $25 y at baseline
(1995–1997) residing in Canada [44]. Interviews and measure-
ments were repeated at 5 and 10 y after enrollment; participant
retention remained at 67% at the tenth year. A similar approach
was used to enroll a youth cohort of individuals aged 16–24 y at
recruitment (2004–2006). Ethics approval for the study was
obtained from the ethics review board at each institution involved
Vitamin D Binding Protein and Disease
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in the study, and all participants gave written informed consent in
accordance with the Helsinki declaration. The current study
sample included 2,254 participants $16 y of age for whom
genotyping for SNP rs2282679 was obtained (adult cohort,
n = 2,122; youth cohort, n = 132).
The large-scale GWAS international consortia used to replicate
CaMos findings of the influence of rs2282679 on traits and disease
were the following: (1) METASTROKE, a collaborative meta-
analysis of ischemic stroke GWAS data comprising 15 cohorts
(12,389 cases/62,004 controls) of European ancestry from the
International Stroke Genetics Consortium (ISGC) [45]; (2) the
Genetic Factors for Osteoporosis Consortium (GEFOS), which
meta-analyzed genetic data and bone mineral density (BMD)
measurements from 17 GWASs comprising 32,961 individuals of
European and East Asian ancestry [46]; (3) the Diabetes Genetics
Replication and Meta-analysis (DIAGRAM) Consortium, which
combined samples from 9,580 cases of type 2 diabetes and 53,810
controls of European ancestry [47]; (4) the International Consor-
tium for Blood Pressure (ICBP), which meta-analyzed genetic data
on blood pressure indices from 28,775 individuals of European
descent [48]; (5) the Meta-analyses of Glucose and Insulin-Related
Traits Consortium (MAGIC), which meta-analyzed 21 GWASs
comprising up to 46,186 non-diabetic individuals to identify
genetic loci that impact glycemic and metabolic traits [49]; (6) the
Genetic Investigation of Anthropometric Traits (GIANT) Con-
sortium, which meta-analyzed data from ,170,000 participants to
identify genetic loci associated with body mass index (BMI) and
other anthropometric traits [50]; (7) the Coronary Artery Disease
Genome Wide Replication and Meta-analysis (CARDIoGRAM),
a meta-analysis of 14 GWASs of individuals of European descent
for coronary artery disease [51]; and (8) SUNLIGHT, a meta-
analysis GWAS of 33,996 individuals from 15 cohorts in Europe
and North America [26].
CaMos Data Collection
Data collection at baseline employed an extensive interviewer-
administered questionnaire that included socio-demographic
information, medical and family history, general health, medica-
tion and supplement use, and food intake. ‘‘Ethnicity’’ was
determined by self-report; indication of an ethnicity other than
‘‘white’’ or ‘‘European’’ was considered ‘‘non-European.’’ Disease
status was ascertained with the following survey question: ‘‘Have
you ever been told by a doctor that you have any of the following
conditions: hypertension, insulin-dependent or non-insulin-depen-
dent diabetes, heart attack, osteoporosis, stroke, or transient
ischemic attack, among other health conditions?’’ Participants
were considered a positive case if they had ever responded ‘‘yes’’
during one of the interviews conducted in year 0, 5, or 10. We
investigated cardiometabolic and calcium-related common diseas-
es with a prevalence of at least 5% (n.100) in the study
population.
Clinical Assessments
Clinical assessments included height and weight measurements
to calculate BMI using the following formula: weight (in
kilograms)/height (in meters)2. BMD was measured at the femoral
neck using a DXA Hologic QDR 1000, 2000, or 4500 bone
densitometer (Hologic, Marlborough, Masschusetts, US) or a
Lunar DPX bone densitometer (Lunar, Piscataway, New Jersey,
US). BMD at the femoral neck was chosen as the standard
osteoporosis-related outcome as it is not confounded by non-
osteoporotic degenerative changes. Lunar data were converted
into equivalent Hologic values by standard methods [52,53]. A
detailed description of BMD quality control appears elsewhere
[54].
Laboratory Measurements
An automated immunoturbidimetric assay (Dako, Glostrup,
Denmark) was used to measure serum DBP concentration. The
assay was configured for the Roche Modular P System (Roche
Diagnostics, Laval, Quebec, Canada). The assay was linear within
the calibration range (28 to 544 mg/l), and the measurable range
could be expanded with sample dilution. The imprecision of the
DBP mass assay was 2.2% at 275 mg/l (Dako Low QC) and 1.4%
at 365 mg/l (in-house quality control). Comparison with an
established binding capacity assay showed close correlation
(r = 0.86, p,0.0001). Serum total 25OHD and PTH were
measured using the Liaison (DiaSorin, Stillwater, Minnesota,
US) autoimmunoanalyzer, using chemiluminescent immunoassay
technology. Details of the assay were described previously [55].
Estimated glomerular filtration rate was calculated using the
Chronic Kidney Disease Epidemiology Collaboration formula
[56].
Genotyping
Genotyping was performed using the Applied Biosystems (ABI)
TaqMan protocol. The SNP rs2282679 had a minor allele
frequency of 0.288, with no evidence for deviation from Hardy–
Weinberg equilibrium (p = 0.89). Three other 25OHD-level-
associated SNPs previously implicated in GWASs [26],
rs12785878 (11q12 near DHCR7), rs10741657 (11p15 near
CYP2R1), and rs6013897 (20q13 near CYP24A1), were also
genotyped.
Linear Regression of SNP and DBP Level
All statistical analyses were undertaken using the STATA
software package (version 11, StataCorp, College Station, Texas,
US). Descriptive statistics of DBP, relevant covariates, and
outcomes were assessed. We visually inspected for normality in
the distribution of DBP levels in our study population and
excluded extreme outliers (.600 mg/l; ,3.5 standard deviations
[SD] from the mean). Further data transformation was not
required. A univariable linear regression model was used to assess
the association of SNP rs2282679 (coded as 0, 1, and 2, as the
count of the C allele) with DBP level (response variable). Results
were then adjusted using a multivariate model that included socio-
demographic characteristics: age, sex, and ethnicity (European or
non-European ancestry).
Observational Regression Analysis of DBP Level and
Clinical Phenotypes
To explore the effect of DBP on phenotypes (common diseases
and related traits), we first visually inspected for normality in the
distribution of all continuous variables and excluded any extreme
outliers (,3.5 SD from the mean; ,1% of all data points).
Logarithmic transformation was performed for PTH and fasting
insulin. The native distribution was used for 25OHD, calcium,
BMI, and BMD. We then generated linear regression models for
continuous outcomes (e.g., BMI) and logistic regression models for
binary outcomes, adjusted for age and sex. Effect estimates were
presented per 1-SD (50 mg/l) increase in DBP. Missing data
points were assumed to be missing at random; thus, complete case
analyses were performed. We used the adult and youth cohorts to
determine the associative effect of DBP on clinical and laboratory-
measured traits, i.e., circulating 25OHD, PTH, calcium, fasting
glucose and fasting insulin levels, and BMI. As the youth cohort
Vitamin D Binding Protein and Disease
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had low risk for the common diseases in question (i.e., myocardial
infarction, diabetes, hypertension, and cerebrovascular accidents),
we explored the effect of DBP on diseases only in the adult cohort.
Multiple Variable Regression of SNP and Phenotypes
We then examined the association of SNP rs2282679 with the
phenotypes (common diseases and related traits) using linear
regression for continuous variables and logistic regression for
binary variables, adjusting for age and sex. The null hypothesis
was tested using a= 0.05. The Bonferroni method was used to
maintain family-wise error rate when performing multiple testing
through enforcing a more stringent a for declaring statistical
significance for each comparison (0.05/12 = 0.004 for 12 com-
parisons). Conservatively, independence between outcomes was
assumed for this correction.
Instrumental Variable Analysis of DBP and Clinical
Phenotypes
We used the SNP as an IV to estimate the causal effect of DBP
on the same outcome measures. For continuous outcomes we used
the two-stage least-squares estimator method that regressed each
outcome against predicted values of DBP level per genotype using
the command ‘‘ivreg2’’ in the STATA software package. The
Durbin-Wu-Hausman chi-square test [57], a test for endogeneity
in a regression estimated via IVs, was computed using the
command ‘‘ivendog,’’ where the null hypothesis states that an
ordinary least-squares estimator of the same equation would yield
consistent estimates. For dichotomous outcomes (e.g., myocardial
infarction), we conducted a two-stage IV analysis. The first stage
was a linear regression of the intermediate phenotype (DBP) on the
categorical instrument (SNP) to generate DBP fitted values. The
second stage was a logistic regression of the clinical outcome on
predicted values of the intermediate phenotype, adjusted for age,
sex, and the estimated residuals that may be correlated with
unmeasured confounders. IV analysis for dichotomous outcomes
has been described previously [58].
Single SNP Look-Ups in GWAS International Consortia
We sought replication of the associations of rs2282679 with
these phenotypes in publically available GWAS meta-analysis data
from large international consortia that provided single SNP look-
up results. Results for this SNP were provided for the following
phenotypes: BMI from GIANT [50], BMD from GEFOS [46],
type 2 diabetes from DIAGRAM [47], blood pressure measure-
ments from ICBP [48], ischemic stroke from METASTROKE/
ISGC [45], and fasting insulin and fasting glucose from MAGIC
[49]. Using this SNP (instrument) as the proxy measure in genetic
association analysis, these large consortia provided at least 90%
power to detect direct associations between rs2282679 (proxy
exposure) and continuous outcome variables given a 2% change in
the mean of the outcome variable per 1-SD change in DBP with
type 1 error rate = 0.004 [59]. Power estimations are shown in
Tables S1 and S2.
Association Analysis of Three Other Vitamin-D-Associated
SNPs with Phenotypes
We used univariable linear regression models to determine the
association of three other vitamin-D-associated SNPs, rs12785878,
rs10741657, and rs6013897, with 25OHD level, and evaluated the
association of all four SNPs, including rs2282679, with 25OHD
level in a multivariate regression model adjusting for age, sex,
ethnicity, and season of blood draw. We then performed single
SNP look-ups for these three additional genetic variants in the
GWAS meta-analysis data for the same traits and diseases that
were tested in CaMos.
Results
We tested the relationships between rs2282679, DBP, and
25OHD in 2,254 CaMos participants; 69.5% were women, and
79.5% were of European descent. The mean age was 65.7 (SD
15.4) y, and mean BMI was 27.5 (SD 5.4) kg/m2 at the time of
clinical assessment. The C allele at rs2282679 had a population
frequency of 0.288; genotype frequencies were 0.514 (AA), 0.396
(AC), and 0.090 (CC) (Table 1). We refer to the C allele as the
effect allele. Individuals carrying the effect allele had lower DBP
levels than those with the more common allele (AA: 384.6 mg/l
[SD 48.3], n = 1,159; CA: 360.7 mg/l [SD 45.9], n = 893; CC:
322.9 mg/l [SD 39.1], n = 202). The effect allele showed an
inverse linear relationship with DBP level (Figure 1). Univariable
linear regression demonstrated a strong relationship between
rs2282276 and DBP level (each copy of the effect allele, C, was
associated with a decrease of 27.6 [95% CI 24.8, 30.4] mg/l in
DBP levels, p = 3.3610276). The rs2282679 SNP explained 14.1%
of the variance in DBP level (coefficient of determination,
r2 = 0.141, F-statistic = 368.7). Adjusted for age, sex, and ethnicity,
the effect size of this SNP on DBP was similar (227.4 [95% CI
230.0, 224.7] mg/l); the variance explained was 25%, while the
F-statistic was 188.7.
While DBP level was associated with age, sex, and ethnicity
(Table 2), rs2282679 was not associated with age, sex, ethnicity, or
any of the following potential confounders: education beyond high
school, sunlight exposure, and smoking status (Table S3). Thus,
rs2282679 remained a suitable genetic instrument for DBP level in
MR analyses. The association for rs2282679 remained robust
(226.5 [95% CI 229.2, 223.8] mg/l) after additionally adjusting
for other potential confounders (i.e., season of blood draw,
education beyond high school, sunlight exposure in the last year,
and smoking status) (Table S4). This SNP also explained 1.5% of
the variance in 25OHD level (F-statistic = 34.6).
There was no evidence of non-linearity in the relationship
between DBP concentration and 25OHD concentration (Figure
S1). Observational analysis demonstrated DBP levels to be
strongly associated (p#0.004) with changes in 25OHD levels
(5.0 [95% CI 3.9, 6.1] nmol/l per 1-SD increase in DBP), calcium
levels (0.01 [95% CI 0.01, 0.02] mmol/l per 1-SD increase in
DBP), and BMI (20.5 [95% CI 20.7, 20.3] kg/m2 per 1-SD
increase in DBP) (Table 3). Weak evidence for association (p#0.1)
was observed between DBP and fasting glucose (20.001 [95% CI
20.002, 27.261025] mmol/l per 1-SD increase in DBP), diabetes
(odds ratio [OR] 0.79 [95% CI 0.66, 0.95]), hypertension (OR
0.91 [95% CI 0.82, 1.01]), and stroke/transient ischemic attack
(TIA) (OR 0.83 [95% CI 0.68, 1.02]). No association was found
with the other phenotypes tested, i.e., fasting insulin, PTH, BMD,
osteoporosis, and myocardial infarction (p.0.1).
Mendelian Randomization Analyses in the CaMos Cohort
Using the SNP for MR analyses, DBP levels were shown to have
a causal effect on only 25OHD levels (8.2 [95% CI 5.2, 10.9]
nmol/l per 1-SD increase in DBP). The other observational
associations described above did not persist in the IV analysis,
suggesting that associations from the observational regression
analyses were non-causal. Assessment for endogeneity indicated
that IV testing was particularly meaningful for estimating effects of
DBP on 25OHD level (p = 0.01), BMI (p = 0.01), and insulin level
(p = 0.02). A suggestive causal association between DBP level and
Vitamin D Binding Protein and Disease
PLOS Medicine | www.plosmedicine.org 4 October 2014 | Volume 11 | Issue 10 | e1001751
stroke/TIA was found, but this association did not survive
multiple-testing correction (OR 0.51 [0.32, 0.81], p = 0.004).
In a subgroup analysis, we explored the relationship between
DBP and traits using the same IV analysis restricted to CaMos
participants with 25OHD levels ,50 nmol/l (n = 498). In this
subgroup, we found that a similar genotype–phenotype relation-
ship was preserved (227.0 [95% CI 232.4, 221.6] mg/l change
in DBP for each copy of the effect allele, C, at rs2282679;
p = 4.8610221; r2 = 0.16, F-statistic = 97.2). Among all the traits
tested, higher DBP level was found to be associated only with
lower calculated free 25OHD level (21.1 [95% CI 21.3, 20.9]
pmol/l for every 1-SD increase in DBP) in the observational
regression analysis; this relationship persisted in the IV analysis
(21.7 [95% CI 22.2, 21.2] pmol/l per 1-SD increase in DBP)
and genetic association analysis (0.9 [95% CI 0.6, 1.2] pmol/l per
copy of the effect allele).
Single SNP Look-Up from Large-Scale GWAS International
Consortia
In order to provide more precise effect estimates in MR analyses
for any particular disease or trait, we replicated our findings of no
association between rs2282679 and common diseases and traits
using data from the large-scale international GWAS consortia
outlined in Table 4. Each of these consortia had adequate power
to test our findings at smaller effect sizes.
SNP rs2282679 was found to be strongly associated with
25OHD level in SUNLIGHT (n = 33,996, p = 1.96102109).
However, there was no association between this SNP and other
common diseases and traits tested, and, importantly, the
confidence intervals for each association were tightly centered at
the null. Thus, our findings suggest a lack of causal effect of DBP
level on these traits and diseases.
Association of Three Other Vitamin-D-Associated SNPs
with Phenotypes
In CaMos, although rs2282679 demonstrated the strongest
association with 25OHD across all SNPs tested, two other SNPs
involved in vitamin D metabolism (rs12785878 [11q12 near
DHCR7] and rs10741657, [11p15 near CYP2R1]) were also
found to be associated with 25OHD level, with or without
adjustment for age, sex, ethnicity, and season of blood draw. A
third SNP, rs6013897 (20q13 near CYP24A1), also previously
implicated in vitamin D metabolism, was not significantly
associated with 25OHD level (Table S6). Single SNP look-ups in
large GWAS meta-analysis results (Table S7) revealed that all
three SNPs were strongly associated with 25OHD level in
SUNLIGHT (rs12785878: p = 2.1610227; rs10741657:
p = 3.3610220; rs6013897, p = 6.0610210). rs6013897 was also
found to be associated with BMD measurements at a threshold
below genome-wide significance in GEFOS (p = 3.0461025). We
observed no other associations between these SNPs and other
calcemic or cardiometabolic traits.
Discussion
Our study documented a strong association between SNP
rs2282679 and both serum DBP and 25OHD levels. As this SNP
explained a large proportion of the variance in DBP levels, it
enabled us to use this polymorphism in causal IV analyses to
demonstrate that DBP levels are unlikely to have a causal role in
all other tested traits and diseases. These observations, from large
sample sizes, suggest that if 25OHD level does influence risk of
these diseases, DBP level has little role in mediating this effect.
Each additional copy of the effect allele at rs2282679 lowered
DBP concentration by 27.6 mg/l (95% CI 24.8, 30.4;
p = 3.25610276) and explained 14.1% of its variance. Further,
this effect allele was strongly correlated with reduced circulating
25OHD concentration (24.3 nmol/l [95% CI 25.9, 22.7];
p = 8.061028) in our study population and explained 1.5% of the
variance in 25OHD level; only an additional 1.1% was explained
by the other three vitamin-D-related SNPs, and another 3.5% by
socio-demographic and environmental factors (Table S6). SNP
rs2282679 may thus define genetic susceptibility to vitamin D
deficiency in certain individuals and may also partly explain the
differential increments in circulating 25OHD in response to
vitamin D supplementation and ultraviolet light exposure. This
Table 1. Participant characteristics for the CaMos cohort.
Characteristic Value
Participant characteristics (n = 2,254)
Female 1,567 (69.5%)
Age—years 65.72 (SD 15.4)
BMI—kg/m2e 27.49 (SD 5.4)
European descent 2,133 (94.6%)
Education beyond high school* 1,183 (52.5%)
No sunlight exposure in last year* 1,151 (51.1%)
Ever smoker* 1,062 (47.1%)
Cold season blood draw" 1,243 (55.2%)




Laboratory measurements (normal range) (n = 2,254)
BMD at femoral neck—g/cm2 0.741 (SD 0.131)
Estimated GFR—ml/min ($60) 78.9 (SD 19.1)
25OHD—nmol/l ($75) 68.9 (SD 24.7)
Free 25OHD—pmol/l 14.4 (SD 5.1)
DBP—mg/l 369.6 (SD 50.1)
Calcium—mmol/l (2.13–2.60) 2.38 (SD 0.11)
Albumin—g/l (34–48) 44.2 (SD 2.6)
PTH—ng/l (22.2–108.9)I 62.4 (SD 30.6)
Fasting glucose—mmol/l (3.3–6.0) 5.51 (SD 1.11)
Fasting insulin—pmol/l 65.4 (SD 44.6)
Diseases6 (n = 2,122) (adults only)
Hypertension 916 (43.2%)
Diabetes 201 (9.5%)
Myocardial infarction 192 (9.0%)
Stroke/TIA 161 (7.6%)
Osteoporosis 475 (22.8%)
Continuous traits are presented as mean (SD), while dichotomous traits are
presented as n (percent). Unless otherwise stated, characteristics had ,2%
missing data.
eMissing data for 87 (3.9%) participants.
*Education beyond high school, sunlight exposure, and smoking were
ascertained in the adult cohort only.
"Cold season blood draws are laboratory blood tests performed between
November and April inclusively.
IMissing data for 171 (7.6%) participants.
uDisease data were obtained only among those genotyped in the adult cohort
(n = 2,122); GFR, glomerular filtration rate.
doi:10.1371/journal.pmed.1001751.t001
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effect allele was common in the population (minor allele
frequency = 0.29) and explained a large proportion of the variance
in DBP level, which highlights a direct mechanism of action
between the gene and circulating levels of the protein and provides
an ideal IV for a MR study. Results from our study indicate that
DBP was causally responsible for circulating 25OHD level
(p = 3.16610219).
Given that serum 25OHD concentration has an inverse
relationship with PTH concentration, PTH level can be used as
a functional readout for 25OHD level. Increased 25OHD levels
are associated with increased calcium absorption, which may
increase serum calcium and decrease production and secretion of
PTH. Increased 25OHD levels may also result in augmented renal
and/or parathyroid conversion of 25OHD to 1,25-dihydroxy-
vitamin D (1,25OH2D). The consequent increase in either
systemic or local production of 1,25OH2D can decrease PTH
gene expression, and reduce PTH production [60,61]. However,
while DBP level strongly correlates with 25OHD level, our results
indicate that DBP concentration does not influence PTH
concentration. We recently reported that, in this largely vitamin-
D-sufficient cohort, while total and free 25OHD levels correlated
negatively with PTH, this relationship is mainly independent of
DBP concentration [61]. In mice with targeted deletion of the Gc
gene that completely lack DBP, PTH levels were not different
between controls and animals without vitamin D toxicity or
prolonged vitamin D deficiency (25OHD #6 ng/ml [15 nmol/l])
Table 2. Unadjusted and multiple-adjusted linear regression association of rs2282679 with vitamin D binding protein serum
concentrations.
Model Variable Change in DBP (mg/l) (95% CI) p-Value r2 F-Statistic
Univariable model (n = 2,248) rs2282679 (C) 227.6 (230.4, 224.8) 3.3610276 0.14 368.7
Multivariate model (n = 2,247) rs2282679 227.4 (230.0, 224.7) 1.3610284 0.26 197.3
Female 29.2 (25.4, 32.9) 2.7610250
Age—years 20.6 (20.7, 20.5) 3.4610226
Age—decades 26.2 (27.3, 25.0)
Non-European 216.9 (224.9, 29.0) 2.861025




















Figure 1. Boxplot of vitamin D binding protein levels by rs2282679 genotype. rs2282679 has three genotypes, i.e., AA, AC, and CC.
Homozygous carriers of the major allele (AA) comprised 51.4% of the population, heterozygous carriers (AC) comprised 39.6%, and homozygous
carriers of the minor allele (CC) comprised 9.0%. Individuals carrying the effect allele, C, had lower DBP levels than those with the more common allele
(AA: 384.6 mg/l [SD 48.3], n = 1,159; CA: 360.7 mg/l [SD 45.9], n = 893; CC: 322.9 mg/l [SD 39.1], n = 202). The effect allele showed an inverse linear
relationship with DBP levels.
doi:10.1371/journal.pmed.1001751.g001
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[23]. Our current MR study supports these findings. A recent study
by Powe and colleagues [62] reported that only slightly higher PTH
levels were found among black Americans with lower total 25OHD
concentrations and DBP concentrations than among white Amer-
icans with lower total 25OHD concentrations and DBP concen-
trations, consistent with our findings. Powe and colleagues also
identified that the large differences in 25OHD levels observed
between black and white Americans are likely due to differences in
DBP levels, which, once accounted for, lead to similar levels of
bioavailable 25OHD in the two ethnic groups [62]. While these
findings may have considerable impact on definitions of vitamin D
deficiency, findings from our study do not provide evidence that
differences in DBP levels impact risk of the common diseases tested.
MR studies have several advantages over observational studies.
As genetic variants are stable throughout life, reverse causality and
other forms of biases commonly associated with observational
studies are removed; this strengthens causal associations between
exposures and outcomes [63]. Indeed, given that the distribution
of the genetic variation in the population is largely a random
process (i.e., random assortment at meiosis), conclusions from MR
studies can be likened to those from randomized controlled trials.
In our study, the point effect estimate of DBP level on 25OHD
level (8.39 nmol/l [95% CI 5.55, 11.22]) from our IV analysis was
larger than the observational effect estimate (5.03 nmol/l [95% CI
3.92, 6.14]; test for endogeneity p = 0.01), suggesting that
circulating 25OHD concentration may depend even more strongly
on DBP level than as is seen in observational studies. Conversely, the
similar effect estimates from IV and observational analyses for fasting
glucose, BMD, calcium, and PTH suggest that these observational
associations are unlikely to be biased by confounding or reverse
causality. Indeed, this MR analysis has further refined our under-
standing of the clinical significance of DBP as a biomarker, and
demonstrates that this serum protein is not a critical player in a causal
pathway potentially linking vitamin D to the common diseases assessed.
While MR is able to strengthen causal inference, it faces
potential limitations [49,64]. Confounding can occur if polymor-
phisms in linkage disequilibrium with rs2282679 also have
phenotypic effects related to the common diseases tested. We
were also not able to account for possible pleiotropic effects of GC
on physiologic pathways that could have masked tested associa-
tions. Null results could also be explained by canalization, i.e.,
phenotypic effects of genetic variations may be buffered during
development [65]. Population stratification can also confound
genotype–disease relationships if the association is influenced by
factors related to population structure. Notably, adjusting for
ethnicity in our regression models did not change the strength of
associations. However, given that the overwhelming majority of all
populations tested were of European descent, our findings are only
applicable to those of European ancestry. Further, all tested
populations in international consortia were primarily of European
Table 3. Observational and instrumental variable analyses for the causal association of vitamin D binding protein with 25-hydroxy-
vitamin D and common diseases and related traits in the CaMos cohort.





50 mg/l of DBP (95% CI) p-Value
Effect Estimate per
50 mg/1 of DBP (95% CI) p-Value
Trait (youth and adult cohorts;
up to n = 2,254)
25OHD—nmol/l 4.99 (3.91, 6.07) 3.2610219 8.17 (5.42, 10.91) 5.561029 0.01
Free 25OHD—pmol/l 20.71 (20.94, 20.47) 3.161029 20.11 (20.71, 0.49) 0.49 0.03
Calcium—mmol/l 0.01 (0.01, 0.02) 1.561025 0.01 (20.003, 0.02) 0.12 0.87
PTHI—ng/l 20.01 (20.03, 0.01) 0.21 0.02 (20.03, 0.07) 0.34 0.11
Fasting glucose —mmol/l 20.001 (20.002, 27.261025) 0.03 23.661024 (20.02, 0.02) 0.73 0.59
Fasting insulinI —pmol/l 20.02 (20.05, 0.01) 0.20 0.06 (20.01, 0.13) 0.11 0.02
BMI—kg/m2 20.53 (20.76, 20.29) 9.161026 0.15 (20.43, 0.72) 0.61 0.01
BMD at femoral neck—g/cm2 0.002 (20.003, 0.007) 0.46 20.005 (20.02, 0.01) 0.43 0.23
Disease (adult cohort only;
up to n = 2,122)
Stroke/TIA 0.83 (0.68, 1.02) 0.08 0.51 (0.32, 0.81) 0.004 —
Myocardial infarction 0.90 (0.75, 1.08) 0.25 0.80 (0.53, 1.21) 0.29 —
Diabetes 0.79 (0.65, 0.96) 0.02 1.00 (0.66, 1.53) 0.98 —
Hypertension 0.91 (0.82, 1.01) 0.09 0.82 (0.64, 1.05) 0.11 —
Osteoporosis 0.96 (0.85, 1.09) 0.53 1.32 (0.97, 1.79) 0.07 —
Effect estimates are presented as absolute changes for continuous traits or ORs for disease per 1-SD increase in DBP. All observational regression and IV models were
adjusted for age and sex only. Analyses of disease conditions were restricted to the adult cohort only. The null hypothesis is tested using a= 0.05. The Bonferroni
method is used to maintain family-wise error rate when performing multiple testing through enforcing a more stringent a= 0.05/12 = 0.004 (12 comparisons).
*The Durbin-Wu-Hausman chi-square test (test for endogeneity) was computed for continuous outcomes.
IThe outcome was transformed using the natural logarithm, and effect estimates are reported accordingly.
Effect estimates with and without excluding participants with diabetes were similar for fasting glucose. Excluding participants with diabetes, effect estimate per 50 mg/
l of DBP: 21.361024 (95% CI 20.001, 3.961024), p = 0.63, and 0.001 (95% CI 20.001, 0.002), p = 0.47, test for endogenicity, p = 0.33; they were also similar for fasting
insulin. Excluding participants with diabetes, effect estimate per 50 mg/l of DBP: 22.461024 (95% CI 20.001, 3.461024), p = 0.42, and 0.001 (95% CI 21.961024, 0.003),
p = 0.09, test for endogenicity, p = 0.03.
doi:10.1371/journal.pmed.1001751.t003
Vitamin D Binding Protein and Disease

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Vitamin D Binding Protein and Disease
PLOS Medicine | www.plosmedicine.org 8 October 2014 | Volume 11 | Issue 10 | e1001751
descent, making confounding by population stratification unlikely.
We also acknowledge that our results are generalizable only to
largely healthy, community-dwelling adults and not to infants,
children, pregnanct women, or periods of human growth and
development.
Another potential limitation of genetic association studies is
unreliable genotype–intermediate phenotype associations [66]. This
is unlikely in this case, as not only does rs2282679 explain 14.1% of
the variance in DBP level, but it is also strongly associated with DBP
level (CaMos, p = 3.3610276, n = 2,254; TwinsUK, p = 4.0610242,
n = 1,674 [26]). While the large variance explained and power
anticipated from this single SNP made it an ideal candidate for a
genetic instrument for DBP, we acknowledge that this instrument
conveys only one aspect of the overall vitamin D status in common
diseases, and therefore can assess the causal effect of 25OHD level
on common diseases only as mediated by DBP level. Three other
SNPs previously implicated in the synthesis or metabolism of
vitamin D (rs12785878, rs10741657, and rs6013897) were found to
be strongly associated with 25OHD level in SUNLIGHT
(rs12785878: p = 2.1610227; rs10741657: p = 3.3610220;
rs6013897, p = 6.0610210), but were not associated with any other
calcemic or cardiometabolic traits, except for femoral neck BMD. A
large MR study on 25OHD level and blood pressure (n = 146,581)
that used SNPs involved only in the synthesis of vitamin D
(rs12785878 and rs12794714) as genetic instruments reported a
small but significant association with hypertension (OR 0.92 [95%
CI 0.87, 0.97]; p = 0.001) and borderline associations with diastolic
(20.29 mm Hg [95% CI 20.52, 20.07] per 10% increase in
25OHD level; p = 0.01) and systolic blood pressure (20.37 mm Hg
[95% CI 20.73, 0.003]; p = 0.052) [67]. However, the clinical
implications of these possible effects have yet to be elucidated.
A study limitation is that biochemical information was cross-
sectional, which prevents us from examining the impact of
biological variability in DBP level over time on common diseases,
and that our study has modeled a linear relationship between DBP
and common diseases. Although we were able to replicate our MR
findings using large GWAS data for the majority of diseases and
traits, we were not able to do so for PTH; thus, smaller effects of
DBP on PTH level may remain undetected by our study. Further,
while stroke and TIA were determined in CaMos by self-report
through a single interview question, METASTROKE had GWAS
data only on ischemic stroke and its subtypes, not TIA.
Hypertension was ascertained in CaMos by self-report and not
blood pressure measurements, whereas ICBP provided publically
available GWAS data on blood pressure measurements and not
hypertension. Observational regression analyses showed that DBP
level was associated with BMI (p = 9.161026); however, this
association was absent in IV analysis (p = 0.46), which is consistent
with previous large-sale MR studies of BMI and 25OHD level [68]
and suggests the presence of an endogenous regressor (p = 0.01).
Such observational associations require instrumenting as they are
potentially spurious because of unmeasured confounders or
affected by reverse causality. Likewise, we provide data demon-
strating a lack of causal relationship between DBP level and all
tested common diseases and traits, except 25OHD level, from
large and well-powered international consortia.
Some evidence suggests that 25OHD level may exert different
threshold effects on PTH level and on skeletal outcomes. High
serum concentrations of 25OHD (.100 nmol/l) have markedly
diminished effects on PTH level [55]. A meta-analysis of effects of
vitamin D supplementation by Reid and colleagues showed
improvement in BMD at the femoral neck mainly in individuals
with baseline 25OHD ,50 nmol/l and not .50 nmol/l [69]. It is
therefore possible that 25OHD may have an appreciable impact
on non-skeletal outcomes only at levels ,50 nmol/l. However, we
note that among CaMos participants, DBP level has no obvious
threshold effect (or any other non-linear relationship) on 25OHD
or log-PTH levels (Figures S1 and S2, respectively).
In our subgroup analysis of participants with 25OHD levels ,
50 nmol/l, among all the traits tested, DBP was causally associated
only with calculated free 25OHD level. Importantly, calculated
free 25OHD level is assessed using DBP level, and thus this
association is to be interpreted with caution. A future study using
laboratory-measured bioavailable 25OHD level can be performed
to test whether these associations can be replicated in larger
cohorts of vitamin-D-deficient participants.
In sum, this MR study, with replication of null findings in large-
scale GWAS meta-analyses, demonstrates that while a strong
causal relationship exists between serum DBP and 25OHD level,
DBP level is not causally associated with any of the calcemic and
cardiometabolic common diseases tested. This suggests that if
25OHD does have causal influence on common diseases in the
general population, it likely acts in a manner independent of DBP.
Our results are generalizable to other vitamin-D-replete popula-
tions of community-dwelling healthy adults where the majority
have 25OHD levels .50 nmol/l [70,71]. Three other genetic
variants that strongly influence 25OHD level, and influence
25OHD metabolism in ways independent of DBP, also showed no
effect upon cardiometabolic disease. It remains to be determined
whether 25OHD has a causal effect on these outcomes indepen-
dent of DBP.
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Editors’ Summary
Background. Vitamin D deficiency is an increasingly
common public health concern. According to some esti-
mates, more than a billion people worldwide may be vitamin
D deficient. Indeed, many people living in the US and Europe
(in particular, elderly people, breastfed infants, people with
dark skin, and obese individuals) have serum (circulating) 25-
hydroxy-vitamin D (25OHD) levels below 50 nmol/l, the
threshold for vitamin D deficiency. Vitamin D helps the body
absorb calcium, a mineral that is essential for healthy bones.
Consequently, vitamin D deficiency can lead to calcemic
diseases such as rickets (a condition that affects bone
development in children), osteomalacia (soft bones in
adults), and osteoporosis (a condition in which the bones
weaken and become susceptible to fracture). We get most of
our vitamin D needs from our skin, which makes vitamin D
after exposure to sunlight. Vitamin D is also found naturally
in oily fish and eggs, and is added to some other foods,
including cereals and milk, but some people need to take
vitamin D supplements to avoid vitamin D deficiency.
Why Was This Study Done? Observational studies have
reported that the low levels of serum 25OHD and serum
vitamin D binding protein (DBP, a key determinant of serum
25OHD level) are both associated with the risk of several
common diseases and traits. Such studies have implicated
vitamin D deficiency in cardiometabolic disease (cardiovascu-
lar diseases that affect the heart and/or blood vessels and
metabolic diseases that affect the cellular chemical reactions
needed to sustain life), in some cancers, and in Alzheimer
disease. But observational studies cannot prove that vitamin D
deficiency or DBP levels actually cause any of these diseases.
So, for example, an observational study might report an
association between vitamin D deficiency and type 2 diabetes
(a metabolic disease), but the individuals who develop type 2
diabetes might share another unknown characteristic that is
actually responsible for disease development (a confounding
factor). Alternatively, type 2 diabetes might reduce circulating
vitamin D levels (reverse causation). Here, the researchers
undertake a Mendelian randomization study to determine
whether circulating DBP levels have causal effects on calcemic
and cardiometabolic diseases. In Mendelian randomization,
causality is inferred from associations between genetic
variants that mimic the influence of a modifiable environ-
mental exposure and the outcome of interest. Because gene
variants are inherited randomly, they are not prone to
confounding and are free from reverse causation. So, if low
DBP levels lead to low serum 25OHD levels, and vitamin D
levels have a causal effect on common diseases, genetic
variants associated with low DBP levels should be associated
with the development of common diseases.
What Did the Researchers Do and Find? The researchers
analyzed the association between a genetic variant called
single nucleotide polymorphism (SNP) rs2282679, which is
known to alter DBP levels, and calcemic and cardiometabolic
diseases and related traits in 2,254 participants in the
Canadian Multicentre Osteoporosis Study (CaMos). The
researchers report that there was a strong association
between SNP rs2282679 and both serum DBP and 25OHD
levels among the CaMos participants. However, there were
no significant associations (associations unlikely to have
occurred by chance) between SNP rs2282679 and calcium
level, osteoporosis, or several cardiometabolic diseases,
including heart attacks and diabetes. Moreover, when the
researchers examined publically available genome-wide
association study data collected by several international
consortia investigating genetic influences on disease, they
found no significant associations between rs2282679 and a
wide range of calcemic and cardiometabolic diseases.
What Do These Findings Mean? In this Mendelian
randomization study, DBP level had no demonstrable causal
effect on any of the calcemic or cardiometabolic diseases or
traits investigated, except 25OHD level. Because most of the
participants in CaMos and the international consortia were of
European descent, these findings are applicable only to
people of European ancestry. Moreover, like all Mendelian
randomization studies, the reliability of these findings
depends on several assumptions made by the researchers.
Notably, although this study strongly suggests that DBP level
does not have a causal influence on several common
diseases, it remains to be determined whether 25OHD has
a causal effect on any calcemic or cardiometabolic outcomes
independent of DBP level.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001751.
N The UK National Health Service Choices website provides
information about vitamin D and about how to get vitamin
D from sunshine; ‘‘Behind the Headlines’’ articles describe a
recent observational study that reported an association
between vitamin D deficiency and Alzheimer disease and
the media coverage of this study, other health claims made
for vitamin D, and a randomized control trial that
questioned the role of vitamin D in disease
N The US National Institutes of Health Office of Dietary
Supplements provides information about vitamin D (in
English and Spanish)
N The US Centers for Disease Control and Prevention
provides information about the vitamin D status of the
US population
N MedlinePlus has links to further information about vitamin
D (in English and Spanish)
N Information about the Canadian Multicentre Osteoporosis
Study is available
N Wikipedia has a page on Mendelian randomization (note:
Wikipedia is a free online encyclopedia that anyone can
edit; available in several languages)
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